Clinical Trial Update: IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS. [Phase 3]

View source ↗

Summary

Phase 3 trial update on Immunerecov contributing to improvement in respiratory and immunological response in post-COVID-19 patients (Long Covid).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long COVID-19

Drugs mentioned

• Immunerecov

Snippet

Sponsor: Federal University of São Paulo | Conditions: Long Covid19, Dietary Supplements | Phase 3 | Status: UNKNOWN